🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since MarchSee the stock

Johnson & Johnson posts mixed results, narrows full-year guidance

Published 04/16/2024, 06:45 AM
Updated 04/16/2024, 06:47 AM
© Reuters.  Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance

Johnson & Johnson (NYSE:JNJ) reported mixed financial results for the first quarter of 2024, with adjusted earnings per share (EPS) slightly surpassing analyst expectations, while revenue fell marginally short of estimates. The healthcare giant posted an adjusted EPS of $2.71, which was $0.07 higher than the consensus estimate of $2.64. However, quarterly revenue was a hair's breadth away from consensus, coming in at $21.38 billion against the expected $21.4 billion.

Despite the EPS beat, shares of Johnson & Johnson edged down 1.7% as the market reacted to the slight revenue miss. The company's first-quarter sales saw a 2.3% increase to $21.4 billion, with a notable adjusted operational growth excluding their COVID-19 vaccine at 7.7%. This performance underscores the company's diversification beyond the pandemic-driven product.

Joaquin Duato, Chairman and CEO, commented on the results, highlighting the company's "solid first quarter performance" and the strides made in their portfolio and pipeline. He emphasized Johnson & Johnson's unique impact across healthcare and the milestones reached during the quarter that reinforce their status as an innovation leader.

Innovative Medicine was a standout segment, with operational sales, excluding the COVID-19 Vaccine, growing by 8.3%. This growth was driven by strong performances in Oncology, Pulmonary Hypertension, Immunology, and Neuroscience products. MedTech also showed robust growth, with worldwide operational sales increasing by 6.3%, led by cardiovascular and general surgery products.

Looking ahead, Johnson & Johnson has increased the midpoint for its full-year 2024 operational sales and adjusted operational EPS guidance, signaling confidence in continued growth. The company expects sales of $88 billion to $88.4 billion, compared to the previous forecast of $87.8 billion to $88.6 billion. JNJ sees adjusted earnings of $10.57 to $10.72 per share, compared to the previous guidance of $10.55 to $10.75 per share.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.